Vimarsana
Biggest News Aggregation in the World

Res Clin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Res Clin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Res Clin Today - Breaking & Trending Today

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes - Vimarsana News

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date ...

Newly detected diabetes patients with acute coronary syndrome experience more extensive ischemic myocardial insult: Study - Vimarsana News

Newly detected diabetes patients with acute coronary syndrome experience more extensive ischemic myocardial insult: Study

Greece: A recent study has shown that acute coronary syndrome (ACS) patients with newly detected diabetes mellitus (NDDM) experience heightened cardiometabolic challenges similar to those with...

4 Science-Backed Benefits Of Apple Cider Vinegar – Forbes Health - Vimarsana News

4 Science-Backed Benefits Of Apple Cider Vinegar – Forbes Health

Apple Cider Vinegar: Health Benefits And Possible Side Effects

Source: forbes.com
Stress hyperglycemia leads to worse outcomes in patients with acute type A aortic dissection - Vimarsana News

Stress hyperglycemia leads to worse outcomes in patients with acute type A aortic dissection

China: A recent study has shown that about 40% of the patients with acute type A aortic dissection (ATAAD) have stress-induced hyperglycemia (SIH) and were at higher risk to receive non-surgical...

Insulin Sensitizers May Be Making a Comeback - Vimarsana News

Insulin Sensitizers May Be Making a Comeback

Researchers have identified new uses for insulin sensitizers, including in the treatment of polycystic ovary syndrome and infertility.